A61K 40/13
B-cells
A61K40/13 (B-cells) appears on 134 US grants and 314 published applications in this corpus.
Search patents in A61K- Granted patents
- 134
- Published applications
- 314
- Assignees
- 211
- Inventors
- 655
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 2 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 3 |
| 2003 | 0 | 11 |
| 2004 | 1 | 8 |
| 2005 | 0 | 3 |
| 2006 | 2 | 3 |
| 2007 | 3 | 3 |
| 2008 | 1 | 2 |
| 2009 | 0 | 3 |
| 2010 | 4 | 11 |
| 2011 | 5 | 6 |
| 2012 | 2 | 6 |
| 2013 | 6 | 14 |
| 2014 | 2 | 5 |
| 2015 | 6 | 10 |
| 2016 | 12 | 8 |
| 2017 | 10 | 15 |
| 2018 | 7 | 13 |
| 2019 | 3 | 20 |
| 2020 | 11 | 16 |
| 2021 | 8 | 24 |
| 2022 | 6 | 26 |
| 2023 | 14 | 25 |
| 2024 | 10 | 32 |
| 2025 | 6 | 23 |
| 2026 | 7 | 23 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- T cell manufacturing compositions and methods16 Jun 2026US 12,653,887 B2Biontech US Inc.
- Genetic engineering of B cell receptors and uses thereof in antigen-induced antibody secretion5 May 2026US 12,617,832 B2Ramot at Tel-Aviv University Ltd.
- Methods for treating HPV-associated diseases14 Apr 2026US 12,599,656 B2
- Systems to produce B cells genetically modified to express selected antibodies31 Mar 2026US 12,589,145 B2Fred Hutchinson Cancer Center
- Method of treating autoimmune and inflammatory diseases using B cells10 Feb 2026US 12,544,439 B2Versiti Blood Research Institute Foundation, Inc.
- Influenza estem immunogens8 Oct 2026US 2026/0306612 A1
- Compositions and methods for reducing antigen-specific immunogenicity8 Oct 2026US 2026/0306626 A1The Research Foundation for The State University of New York
- Chimeric engulfment receptor molecules and methods of use8 Oct 2026US 2026/0308281 A1Cero Therapeutics Holdings, Inc.
- Influenza ehead immunogens1 Oct 2026US 2026/0295029 A1The Scripps Research Institute
- Coronavirus s2 immunogens1 Oct 2026US 2026/0295034 A1The Scripps Research Institute
Most cited
By later US patents
- Adjuvant incorporation in immunonanotherapeutics87US 8,637,028 B2Massachusetts Institute of Technology · 2014
- Targeting of antigen presenting cells with immunonanotherapeutics58US 8,343,497 B2Massachusetts Institute of Technology · 2013
- Single chain MHC complexes and uses thereof51US 5,869,270 ASunol Molecular Corporation · 1999
- Adjuvant incorporation in immunonanotherapeutics48US 8,343,498 B2Massachusetts Institute of Technology · 2013
- Targeting of antigen presenting cells with immunonanotherapeutics43US 8,562,998 B2Massachusetts Institute of Technology · 2013